Initial results of Onco KEM and the WINTHER trial were presented at TAT 2017: 15th International Congress on Targeted Anticancer Therapies, 6-8 Mar 2017, Paris, France.
The study demonstrates that the innovative Onco KEM transcriptomic-based decision support system fills a gap left by traditional DNA based targeted therapy, enabling more patients to reach a larger pool of accessible drugs and potentially benefit from precision medicine, even at a late stage of the disease, when no more clinical guidelines exist.
“Initial perspectives from WINTHER, an international precision medicine trial using both DNA and RNA data to guide treatment”
Links: |